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EDITORIAL REVIEW
Parathyroid gland function in chronic renal failure
With the advent of the radioimmunoassay for parathyroid
hormone (PTH) in the 1960's, it was established that the serum
calcium concentration was the most important factor regulating
PTH secretion [1—3]. Subsequent studies determined that: (1)
PTH secretion varies as a function of serum calcium with
hypocalcemia stimulating and hypercalcemia suppressing PTH
secretion [4]; (2) the mathematical model which best relates
PTH and serum calcium is a sigmoidal curve [5—7]; and (3) at
maximal PTH inhibition during hypercalcemia, a non-suppress-
ible component of PTH secretion is present [5, 6, 81. Other
studies performed in patients with renal failure established that:
(1) hyperparathyroidism (HPT) developed during chronic renal
failure [9—11]; (2) skeletal resistance to the calcemic action of
PTH contributed to the development of HPT [12—14]; (3) an
increased dialysate calcium during hemodialysis decreased
PTH levels in dialysis patients [9, 10, 15]; and (4) treatment with
calcitriol reduced PTH levels and improved the bone disease of
dialysis patients with marked secondary (2°) HPT [16—19].
However, in the studies of calcitriol, it was often difficult to
determine whether PTH levels were decreased due to a direct
inhibitory effect of calcitriol or a calcitriol-induced increase in
the serum calcium. Subsequent clinical studies clearly estab-
lished that calcitriol inhibited PTH secretion independent of
changes in the serum calcium [20, 21].
During the past two decades, differences in PTH levels have
been noted in maintenance dialysis patients with different forms
of renal osteodystrophy. The predominant bone disease in the
dialysis patient has been osteitis fibrosa which clinically is the
reflection of marked 2° HPT and is associated with bone
histology that is characterized by an increase in the osteoblast
surface, bone resorption, and the bone formation rate [22—27].
However, during the late 1970's and early 1980's, a significant
number of patients were found to have low-turnover aluminum-
associated bone disease (LTAABD) which was associated with
a relative deficiency of PTH, a decrease in the osteoblast
surface, the presence of stainable bone aluminum, osteoid
accumulation, and a decreased rate of bone formation [27—31].
The term "relative PTH deficiency" has been used because the
absolute PTH level, which may be minimally increased or the
same as in the normal individual, is markedly lower than the
level observed in most dialysis patients. More recently, an
increase in the number of dialysis patients with aplastic bone
disease, which has also been called "adynamic bone disease",
has been reported [7, 27, 32, 33]. These patients also have a
relative PTH deficiency and similar bone histology as patients
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with LTAABD except that stainable bone aluminum is absent
and osteoid accumulation is not observed [7, 27, 33].
Although radioimmunoassays for PTH have been available
since the late 1960's, they often provided imprecise, inconsis-
tent, and non-uniform estimates of biologically active PTH; this
has been especially true in renal failure [24, 25, 32, 34—39].
These problems stemmed from the measurement of different
fragments of PTH. Parathyroid hormone is an 84 amino acid
hormone which is metabolized into amino (1-34) and carboxy
(53-84) terminal portions. Different radioimmunoassays for
PTH measured either the amino, carboxy, or mid-region (28-48)
fragments. Certain radioimmunoassays such as the carboxy and
mid-region do not always reflect biological activity because
biologically inactive fragments accumulate in renal failure [34,
38, 40—42]. While the amino-terminal fragment is biologically
active as proven by the infusion of this PTH fragment [43, 44],
the assay for amino-terminal PTH has been reported to lack
sensitivity in situations such as primary (1°) HPT in which renal
function is normal and HPT is present [35]. Furthermore,
certain PTH fragments may be preferentially secreted during
hypo- and hypercalcemia [8, 45—48]. The introduction of the
immunoradiometric (IRMA) assay to measure intact PTH has
resulted in an important advance because of greater reliability
and precision in the study of HPT both in normal and azotemic
individuals [38, 49]. This PTH assay accurately reflects PTH
secretion during the induction of hypo- and hypercalcemia both
in normal volunteers [5, 50, 51] and in dialysis patients [7, 21,
52—55]. As a result, meaningful comparisons between PTH and
serum calcium can be made irrespective of renal function.
Another PTH assay which has been developed and has been
shown to be sensitive and specific in several reports in the
immunochemiluminometric assay [49, 56]. The principle is the
same as the immunoradiometric assay except that an acridinium
ester-labeled signal antibody is used instead of a radioisotope.
Because the relationship between PTH and serum calcium is
best expressed as a sigmoidal curve and the ambient calcium
concentration may vary considerably in dialysis patients, dy-
namic testing of PTH secretion has been performed to better
assess parathyroid function in azotemic patients [7, 21, 52—55].
The PTH-calcium curve has been determined in dialysis pa-
tients in order to better understand parathyroid disease in
several different situations. These have included: (1) dialysis
patients with different forms of renal osteodystrophy [7, 28, 57,
58]; (2) diabetic dialysis patients [7, 59]; (3) as an indicator of
the effectiveness of specific treatments such as calcitriol for
osteitis fibrosa [20, 21, 55] and desferrioxamine (DFO) for
LTAABD [54]; (4) to determine residual hyperparathyroidism
after renal transplantation [60]; and (5) to assess the response of
the parathyroid gland to directional changes in the serum
calcium during the induction of and recovery from both hypo-
and hypercalcemia [52, 53, 61].
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While many of the earlier studies of the PTH-calcium rela-
tionship provided relevant information about PTH secretion,
we believe that these studies often did not provide maximal
information because of the method by which the PTH-calcium
relationship was presented. For example, it is difficult to
evaluate the direct effect of calcitriol on PTH secretion if the
serum calcium concentration increases as a result of treatment
with calcitriol. Similarly, to know the effect of hypocalcemia on
PTH secretion, it is important to be certain that maximal PTH
secretion has been induced. Such information can be obtained
when the sigmoidal PTH-calcium curve is analyzed appropri-
ately. It is our intent to present a uniform approach for the
study of the PTH-calcium relationship and attempt to analyze
some of the earlier and more recent studies within the frame-
work of this approach. While the primary focus of this editorial
is to review the PTH-calcium relationship in renal failure, in
order to provide the proper perspective, we will also review
studies of the PTH-calcium relationship in the normal human
and in 10 HPT, the other major disorder affecting the parathy-
roid gland. However, before proceeding to an examination of
the clinical studies, we will provide a background for under-
standing the clinical studies by briefly reviewing: (1) the short-
term response and the long-term adaptation of the parathyroid
gland to hypocalcemia; (2) the known in vitro modulators of
PTH release; (3) the terms used to analyze the PTH-calcium
relationship; (4) the in vitro studies of cells from normal and
abnormal parathyroid glands; and (5) the metabolism of intact
PTH.
Regulation of the parathyroid gland response to hypocalcemia
Short-term response to hypocalcemia
The primary function of the parathyroid gland is to protect
against the development of hypocalcemia by the instantaneous
secretion of PTH. Increased PTH levels restore blood calcium
to normal by enhancing renal reabsorption of calcium, bone
resorption of calcium, and over a longer time period, intestinal
calcium absorption; the latter effect is modulated by a PTH-
induced increase in calcitriol production. Furthermore, a rela-
tively small decrement in the serum calcium rapidly produces a
maximal and sustained rise in PTH levels. Recent studies in
normal individuals have indicated that the maximal PTH re-
sponse to hypocalcemia is approximately four- to fivefold
greater than the basal PTH level [5, 50, 51]. While in dialysis
patients the ratio between maximal and basal PTH is less than
the four- to fivefold of that observed in normals [7, 21], the
maximal PTH level in the dialysis patient may be 20 to 50 times
greater than the maximal PTH level in normal individuals [5, 7,
21, 50, 55, 62, 63]. Potential mechanisms by which the parathy-
roid gland maintains a sustained secretion of PTH include a
release of stored PTH, increased synthesis of PTH, changes in
the intracellular degradation of PTH, reutilization of degraded
hormone, and mobilization of a secondary storage pool. Studies
in the cow have demonstrated that sufficient stored PTH is
present to maintain a maximal PTH response for approximately
1 to 1.5 hours [6]. While the time required to increased
synthesis of PTH in humans is not known, studies have
indicated that an increase in PTH messenger RNA requires
more than three hours in the rat [64, 65] and twelve hours in the
cow [66]. Thus, it is unlikely that increased PTH synthesis plays
a major role in the immediate PTH response to hypocalcemia.
Normally, considerable amounts of synthesized PTH are
degraded within the parathyroid gland [67, 681. Under normal
conditions and during hypercalcemia, the parathyroid gland
secretes a carboxy-terminal fragment, the amount of which may
be equivalent or greater than the secretion of intact PTH [8, 45,
47, 69, 701. During hypocalcemia, intracellular degradation of
PTH decreases contributing to the increased secretion of intact
PTH; it has been estimated that approximately forty minutes
are required to change the degradation process [67, 71]. Thus, it
is likely that changes in the pattern of intracellular PTH
degradation contribute to the increased release of intact PTH
during the rapid induction of sustained hypocalcemia. Another
potential mechanism by which the parathyroid gland maintains
an increased release of intact PTH is to reutilize previously
degraded hormone for the synthesis of intact PTH [67, 72].
Finally, there has been the suggestion that a secondary storage
pool of PTH may be available to enhance secretion; however,
the available evidence indicates that agents which increase
intracellular cyclic AMP such as isoproterenol may be more
effective in mobilizing this storage pool than hypocalcemia [67,
71, 73].
Long-term adaptation to hypocalcemia
A primary adaptation to prolonged hypocalcemia is hyper-
plasia of the parathyroid gland [74, 75]. The major factors which
stimulate the development of parathyroid gland hyperplasia are
hypocalcemia and reduced levels of calcitriol [74, 75]. It has
been demonstrated in in vitro and in vivo studies, that both
hypocalcemia and decreased calcitriol levels are potent stimu-
lators of PTH mRNA synthesis [64, 65, 74, 76—81]. Constant
stimulation of PTH mRNA synthesis has been associated with
the development of parathyroid gland hyperplasia [78, 82—84].
Recent studies by Okazaki et a! have shown that a palindrome
sequence around —3.5 kilo base pairs in the 5' flanking region of
the human PTH gene may mediate the suppression of PTH gene
transcription by extracellular calcium [85]. The suppressor
effect of calcitriol has been shown to be due to its binding to a
specific intracellular receptor [86, 87], and is mediated by
regulating the transcription of specific genes which control
regulatory proteins [86, 88]. In the human PTH gene, the
control of transcription has been shown to be mediated by the
sequence at —212 to —353 base pairs in the 5' flanking region of
the PTH gene [81].
Chronic renal failure is a potent stimulus for parathyroid
hyperplasia because both hypocalcemia and low levels of
calcitriol are present. Previous studies in the rat have demon-
strated that by 36 to 72 hours after nephrectomy, a fiftyfold
increase in mitotic activity of the parathyroid gland is observed
[89—91]. Furthermore, in renal failure, suppression of PTH
mRNA may be resistant to physiologic levels of calcitriol, but
may be overcome by pharmacologic levels of calcitriol [791.
This resistance may be due to a decreased number of calcitriol
receptors on the parathyroid gland [92—94]. This finding has
been reported both in patients [93] and animals [92, 94] with
renal failure, and thus may have a role in the development of 20
HPT. However, a recent study has disputed the finding of a
decreased number of receptors, and has suggested that this
result was due to the technique for isolating the receptor [95].




Recent studies have also indicated that the administration of
calcitriol up-regulates the calcitriol receptor in the parathyroid
gland [86] and the intestine [961. The role of up-regulation of
calcitriol receptors by calcitriol and any potential importance in
the prevention of HPT in renal failure remains to be deter-
mined.
In vitro modulation of PTH secretion
Studies of parathyroid cells in culture have provided impor-
tant information on the mechanism of PTH secretion. A sum-
mary of this information provides a useful framework for
understanding PTH secretion in vivo. However, a detailed
analysis of these studies is beyond the scope of this editorial,
and for more information the reader is referred to several
excellent reviews [67, 68, 72, 89, 97]. As is observed with the
parathyroid gland in vivo, parathyroid cells in vitro are sensitive
to changes in extracellular calcium. A low extracellular calcium
concentration stimulates and a high extracellular calcium con-
centration suppresses PTH secretion [48, 72, 89, 98—107]. Other
di- and trivalent ions such as magnesium, barium, strontium,
and lanthanum have been shown to mimic the in vitro effects of
calcium [89, 108, 109]. In addition, aluminum, in concentrations
similar to those observed in dialysis patients with aluminum
toxicity, has also been reported to decrease PTH secretion
during hypocalcemia [110—1121. Of these di- and trivalent ions,
only magnesium is known to have biologic importance in the
normal individual. In vitro studies have indicated that at similar
concentrations, magnesium is two to three times less effective
than calcium in inhibiting PTH release [89, 113, 114]. In a
clinical study performed in pregnant women, hypermagnesemia
induced a decrease in both serum PTH and calcium [1151. It
should also be added that paradoxically, severe hypomag-
nesemia has been shown to inhibit PTH release and produce
hypocalcemia [116—118]. In patients with renal failure, high
serum aluminum levels may decrease PTH secretion [7, 27, 28,
54, 57].
Studies of the parathyroid cell have shown that increasing
extracellular calcium from 0.5 m, a concentration that maxi-
mally stimulates PTH secretion, to 2.0 ms, a concentration that
maximally inhibits PTH secretion, results in a three- to fourfold
increase in cytosolic calcium [89, 99, 119]. This increment in
cytosolic calcium is inversely related to PTH secretion and
mirrors the relationship between extracellular calcium and PTH
secretion [89, 99, 119]. Thus, the parathyroid cell appears to be
different from other secretory cells in which the stimulation of
secretion is mediated by an increase in intracellular calcium
[120, 121].
Terms used to define the PTH-calcium relationship
As previously stated, the PTH-calcium relationship is best
expressed as a sigmoidal curve, As such it is possible to define
the boundaries and limits of this curve and thus use the defined
points to compare individual or groups of patients. Four terms
which help to define the PTH-calcium curve are illustrated in
Figure 1A. The maximal PTH (V1'H represents maximal
PTH stimulation and is defined as the highest PTH level
observed in response to hypocalcemia and which an additional
reduction in the serum calcium does not produce a further
increment in PTH. The minimal PTH (PT}{) represents
maximal PTH inhibition and is defined as the lowest PTH level
observed in response to hypercalcemia and which an additional
increase in the serum calcium does not produce a further
decrement in PTH. The serum calcium concentration at
mal PTH (Caml is defined as the serum calcium concentration
at which maximal PTH is first observed. The serum calcium
concentration at minimal PTH (Ca1 is defined as the serum
calcium concentration at which minimal PTH is first observed.
In addition to the terms illustrated, the basal VFH is defined as
the PTH level at the baseline serum calcium concentration
before any induced changes in the serum calcium.
The terms listed in Figure 1A are applicable whether PTH is
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Fig. 1A. The terms used for the analysis of the PTH-calcium curve are illustrated with values from a hemodialysis patient with marked secondary
hyperparathyroidism and bone-biopsy proven osteitis fibrosa. These terms are defined in detail in the section "Terms used to define the
PTH-calcium relationship." PTHmax is the maximal PTH level, PTHmin is the minimal PTH level, and ICA is the ionized calcium concentration.
B. Shown is an illustration of the slope (— — —) of the PTH-calcium curve and the set point of calcium. When the maximal PTH level is converted
to 100%, the slope of the PTH-calcium curve should provide an assessment of parathyroid cell sensitivity. The formula by which the slope was
calculated is provided and discussed in the section "Terms used to define the PTH-calcium relationship." PTHm,X is the maximum PTH level,
PTHmin is the minimal PTH level, and ICA is the ionized calcium concentration.
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maximal PTH. In both, the serum calcium concentration at
maximal PTH and at minimal PTH would be identical. Simi-
larly, the ratios between the PTH values would be the same
whether PTH is presented as a percent or an absolute number.
For example, for a given PTH value of 1500 pg/mI and with
maximal PTH at 2000 pg/ml, the PTH value of 1500 pg/mi would
be 75% of the maximal PTH. The conversion of PTH from
absolute numbers to percent is done to factor for the difference
in PTH concentration which reflects parathyroid gland mass,
and as such should provide an assessment of the individual
parathyroid cell. Thus, when a maximal PTH level of 2000
pg/mi or 500 pg/ml is converted to percent, each would be
100%.
It is likely that the maximal PTH level reflects the maximal
secretory capacity of the parathyroid gland. As such, it is
probable that the maximal PTH level indicates the mass of
parathyroid secretory cells or after treatment with agents such
as calcitriol, the functional secretory capacity of the parathy-
roid gland. The minimal PTH level is not difficult to define, but
its meaning is more problematic. In the normal individual, this
value is between 5 and 10% of the maximal PTH and thus
reflects a tonic level of PTH secretion that cannot be sup-
pressed. In dialysis patients, the minimal PTH level generally
ranges between 5 and 40% of maximal PTH. As such, there is a
good possibility that the minimal PTH level may also be an
indicator of parathyroid cell mass. The basal PTH level, while
providing important information about the magnitude of HPT,
may be modified by changes in the serum calcium concentration
which are known to vary considerably in the dialysis patient.
Throughout the remainder of this review, the ratio of basal to
maximal PTH and the ratio of minimal to maximal PTH are
used to analyze the operational status of the parathyroid gland.
Even with the use of the IRMA assay for intact PTH, it is clear
that the ratio of basal to maximal PTH and the ratio of minimal
to maximal PTH are greater in hemodialysis patients than in
normal humans [5, 71. This higher ratio of basal to maximal
PTH will result in greater PTH production at the basal serum
calcium concentration. To illustrate this concept, consider the
normal individual. The basal PTH level is 20 to 25 pg/ml and the
maximal PTH level is 100 pg/ml; thus, the ratio of basal to
maximal PTH is 25% and the PTH reserve to hypocalcemia is
four (100 pg/mI divided by 25 pg/mI). However, if the basal to
maximal PTH ratio increases to 50%, then, at baseline, the PTH
level would be 50 pg/ml. This response would result in a greater
PTH level in the basal state, but at the same time would reduce
the PTH reserve during hypocalcemia to two (100 pg/ml divided
by 50 pg/ml). This type of response would increase PTH levels
at baseline without the necessity for parathyroid hyperplasia.
As will be presented later, the hemodialysis patient combines
this type of PTH response with hyperplasia. The minimal to
maximal PTH ratio is another concept which is developed in
this editorial. In the normal human, the ratio of minimal to
maximal PTH is between 5 and 10% [51. However, in the
hemodialysis patient, this ratio may vary from 5 to 40% [7].
Furthermore, after calcitriol treatment the ratio of minimal to
maximal PTH may vary considerably [21, 55], or in other
words, the decrease in maximal and minimal PTH is not always
proportional. The ratio of minimal to maximal PTH should
provide a measure of PTH suppressibility during hypercalce-
mia. However, the reason for disproportional changes in the
maximal and minimal PTH levels in hemodialysis patients after
calcitriol treatment is a question that requires further evalua-
tion.
The terms illustrated in Figure lB have produced more
debate with respect to their interpretation and how each should
be defined. The set ooint of calcium has been defined in in vitro
studies as the calcium concentration which produces a half-
maximal inhibition of PTH secretion [98]. This represents the
mid-point between the maximal PTH and minimal PTH. Thus,
with maximal PTH as 100% and if minimal PTH is 30%, then the
set point of calcium would be observed at 65% of the maximal
PTH [(100 — 30)/2) + 30 = 65]. However, in our clinical studies,
because the minimal PTH level varies considerably in dialysis
patients, we have elected to define the set point of calcium as
the calcium concentration at which the maximal PTH is reduced
by 50% [7, 21, 52, 54, 55]. By our definition, we believe that the
set point of calcium becomes an indicator of the serum calcium
concentration at which PTH secretion is stimulated.
An argument could be made that in vivo, the interpretation of
the set point of calcium should be different than the set point of
calcium as it has been defined for the study of PTH secretion by
parathyroid cells in vitro. The latter is a closed system that is
not influenced by other factors except the external manipulation
of the calcium concentration. However, in normal humans and
animals, the baseline serum calcium concentration is main-
tained at a relatively constant level [122—124] and represents a
steady state of calcium exchange between the bone, kidney,
and gut. Any influence which increases or decreases the serum
calcium results in either an inhibition or stimulation of PTH,
which then rapidly restores the serum calcium to normal by its
immediate effect on bone calcium exchange and renal excretion
of calcium. More delayed is the PTH effect on calcitriol
production and the resultant effect of calcitriol on gut absorp-
tion of calcium. Consequently, we agree with Kurokawa's
concept that the set point of calcium is the overall equilibrium
of calcium for the system [125]. This value for the set point of
calcium would be the result of the calcium equilibrium between
extracellular fluid and bone, and between extracellular fluid and
the kidney. By this definition, the set point of calcium would be
the baseline serum calcium. Thus, through the action of PTH on
the bone, kidney, and indirectly the gut, the system is designed
to correct any deviation from the baseline serum calcium. As a
result, it could be argued that the set point of calcium as has
been defined for most in vivo studies (50% of the maximal PTH
or the mid-range between minimal and maximal PTH) is an
artificial concept that may not apply to a biological system.
In the dialysis patient, the regulation of serum calcium is
considerably different than in the normal individual because the
kidney is non-functional, which results in an inability to regu-
late calcium excretion, and gut absorption of calcium is reduced
because of a calcitriol deficiency. Thus, in the dialysis patient,
the baseline serum calcium concentration is not as likely to be
maintained in a narrow range. Consequently, the biological set
point of calcium for dialysis patients is more difficult to define
because the normal homeostatic mechanisms which maintain
the serum calcium within a narrow range have been dramati-
cally altered.
In clinical studies, we have defined the set point of calcium as
the serum calcium concentration which decreases the maximal
PTH level by 50% [7, 21, 52, 54, 55]. However, this may not
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represent an accurate extrapolation of the term as it was
originally defined for the analysis of the PTH-calcium relation-
ship in the in vitro system. Furthermore, since factors control-
ling the regulation of serum calcium are different between
normal and azotemic individuals, information gained from a
direct comparison of the set point of calcium between these two
conditions must be interpreted with caution. Further thought
should be applied to the definition and meaning of the set point
of calcium for in vivo studies. However, for the remainder of
this review, we will continue to refer to the set point of calcium
as the serum calcium concentration which decreases the max-
imal PTH level by 50% because this definition has been used in
most previous clinical studies.
The other term presented in Figure lB is the slone of the
PTH-calcium curve. As shown in Figure 1B, the maximal PTH
is transformed to 100% to factor for differences in maximal PTH
levels between patients or after treatment with calcitriol. The
slope of the PTH-calcium curve which measures the change in
PTH for a change in calcium should provide information on the
sensitivity of the parathyroid cell. Since maximal PTH is
normalized to 100%, the slope should reflect PTH production
per cell. The slope of the PTH-calcium curve can be defined as
the maximal PTH (A) minus the minimal PTH (D) divided by
the serum calcium concentration at maximal PTH (CAmax)
minus the serum calcium concentration at minimal PTH
(CAmin) or (A — D)I(CAmax — CAmin). However, in dialysis
patients, the flattening at both ends of the sigmoidal PTH-
calcium curve frequently extends over a considerable range of
serum calcium; this would result in a dramatic reduction of the
slope as defined by the method above. Furthermore, we believe
that the sensitivity of the parathyroid cell as defined by the
slope (change in PTH for a change in calcium) is more relevant
physiologically in the more linear portion of the PTH-calcium
curve. Thus, we have elected to calculate the slope of the
PTH-calcium curve in a range from 95% of the maximal PTH
(A) to the minimal PTH (D) plus 5% A. The range of serum
calcium concentration would be from the serum calcium at 95%
A (CA1) to the serum calcium at D + 5% A (CA2). Thus, the
formula for the calculation of the slope is [0.95A — (D/A +
0.05)] x 100/(CA1 — CA2). The value for the slope is expressed
as the zPTH(%)/ calcium (mg/dl). It should also be stated that
our method to calculate the slope of the sigmoidal PTH-calcium
curve is not the only method which has been advocated [98]. In
the other method a logarithmic transformation of PTH, calcium,
and the mid-range set point is performed; this transformation
changes the sigmoidal curve into a straight line. A detailed
comparison of the two methods is beyond the scope of this
review. However, it is our opinion that the method using the
logarithmic transformation is excellent for the calculation of the
slope of a sigmoidal curve provided that the minimal PTH level
(D) as a percent of the maximal PTH (A) remains constant.
However, if the minimal PTH level (D) as a percent of the
maximal PTH (A) varies considerably, as is observed in hemo-
dialysis patients [7, 21, 55], then we believe that this method
may not be optimal for the calculation of the slope of the
sigmoidal PTH-calcium curve.
It is our belief that the PTH-calcium relationship is represen-
tative of parathyroid gland function when analyzed as a two
dimensional model. By plotting PTH versus calcium, the im-
portance of the sigmoidal relationship between these two pa-
rameters can be appreciated, and the PTH-calcium relationship
can be evaluated with respect to maximal PTH, minimal PTH,
the set point of calcium, and the slope of the PTH-calcium
curve.
One final consideration is that in studies in dialysis patients,
the PTH-calcium curve has been evaluated by modulating the
calcium concentration of the dialysate. In all other studies of
the PTH-calcium curve, hypocalcemia has been induced by the
use of a chelating agent, either sodium EDTA or citrate, and
hypercalcemia by an infusion of calcium. Conceptually, it
would seem that changes in the serum calcium by either
technique should produce a similar PTH response. However, to
our knowledge, this has not been evaluated and thus, it would
be important to know whether the removal of calcium by
dialysis produces a different PTH response than calcium bind-
ing by chelation. In addition, as has been performed in several
recent clinical studies [5, 50, 51], incremental increases in the
rate of infusion of a chelator or calcium to achieve a linear
decrease or increase in the serum calcium may produce a
different PTH response than the gradient-dependent rate of
calcium removal or infusion used in hemodialysis studies. In the
former situation during calcium removal, the calcemic effect of
increased PTH levels on bone is neutralized by increasing the
infusion rate of the chelator. In the hemodialysis patient, the
rate of calcium removal should only dependent on the calcium
gradient since the blood flow rate, the dialysate flow rate, and
the dialysate calcium concentration are constant throughout
dialysis. As a result, there is no additional compensation for the
calcemic action of increased PTH levels on bone. Finally, the
rate of calcium infusion may also not be entirely comparable
since in one, the rate of calcium infusion is incremental and in
the hemodialysis studies, the rate of calcium infusion is gradient
dependent, and as such the buffering capacity of bone should
not be negated.
In vitro studies of parathyroid cells derived from adenomatous,
hyperplastic, and normal parathyroid glands
In vitro studies have indicated that the set point of calcium for
PTH secretion is greater in parathyroid cells derived from
adenomatous and hyperplastic parathyroid glands than in nor-
mal parathyroid cells [72, 98, 101-103, 126]. Most of these
studies did not find any difference in the amount of PTH
secreted per cell between cells obtained from normal and those
from adenomatous and hyperplastic parathyroid glands [72,
102, 103]. However, one problem interpreting most of these
studies is that PTH was measured with a carboxy-terminal
antibody and preferential secretion of the carboxy-terminal
fragment of PTH may be observed during hypercalcemia [8,
48]. Cantley et al using an N-terminal assay reported that PTH
secretion was greater in parathyroid cells derived from hyper-
plastic than adenomatous parathyroid glands [106], however,
this study did not include normal parathyroid cells for compar-
ison. In a study in which both the N-terminal and intact PTH
response to hypocalcemia was measured, the release of N-ter-
minal PTH was three to six times greater than intact PTH in a
subset of parathyroid cells derived both from parathyroid
adenomas and hyperplastic parathyroid glands [105]; this was
not true of most cells derived from adenomatous and hyperplas-
tic parathyroid glands. In summary, these studies suggest that
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while an increase in set point of calcium is frequently observed
in cells derived from abnormal parathyroid glands, maximal
PTH secretion per cell does not appear to be different for cells
derived from normal and abnormal parathyroid glands. How-
ever, differences in the secretion of PTH fragments may be
observed in cells derived from some abnormal parathyroid
glands.
Results of in vitro studies have indicated that the slope of the
PTH-calcium relationship, which represents the degree of
change in PTH secretion relative to the change in calcium
concentration (sensitivity), was not different between parathy-
roid cells derived from normal and abnormal parathyroid glands
[72, 98]. Another important aspect of the PTH-calcium relation-
ship is the suppressibility of PTH secretion by an elevation in
the calcium concentration. In abnormal parathyroid glands
perfused in vitro and in the majority of parathyroid cells derived
from abnormal parathyroid glands, an elevation in the calcium
concentration suppressed PTH secretion by more than 50% [72,
102—107]. These studies included cells derived both from ade-
nomatous and hyperplastic parathyroid glands. Furthermore,
this response was not limited to PTH measurement with a
carboxy-terminal assay, but included measurement of both
amino-terminal [105, 106] and intact PTH [105].
The metabolism of intact (1-84) parathyroid hormone
Since in the studies of the PTH-calcium curve the metabolic
clearance rate of intact PTH is not known, it is difficult to be
certain that calcium-induced changes in the PTH level are
entirely due to changes in PTH secretion. Together the liver and
kidney account for approximately 90% of the metabolism of
intact PTH with hepatic degradation responsible for almost
two-thirds [127—130]. Studies in normal animals have demon-
strated a rapid metabolic clearance rate of intact PTH with a
two to five minute half-time of disappearance [127, 131, 1321.
Several factors may affect the metabolic clearance rate of intact
PTH. Renal failure has been reported to decrease the metabolic
clearance rate because of decreased filtration by the kidney [42,
128, 1331. In a study which used an isolated organ perfusion
system, the absence of the kidney resulted in increased hepatic
degradation of intact PTH as measured by an IRMA assay, but
the overall metabolic clearance rate was decreased by approx-
imately 25% [134]. Studies in the azotemic dog and human have
noted that chronic renal failure reduced the capacity of the liver
to metabolize intact PTH [127, 135]. In these studies intact PTH
was not measured with an IRMA assay. If renal failure does
result in reduced clearances of intact PTH, this could result in
an increase in the PTH level, but should not account for
differences when patients with comparable degrees of renal
function are studied. However, a reduced clearance rate of
intact PTH could conceiveably contribute to differences be-
tween normal and azotemic humans, but at present it is not
possible to estimate the magnitude of this effect when intact
PTH is measured with an IRMA assay. Other factors which
may affect the metabolic clearance rate of intact PTH include
the serum calcium concentration and PTH removal during
hemodialysis. In several studies, hypocalcemia has been re-
ported to increase the metabolic clearance of intact PTH [133,
136], but this could not be confirmed in other studies [137].
Another consideration is the possibility that intact PTH is
removed during hemodialysis. However, a recent study has
indicated that removal of intact PTH is negligible during hemo-
dialysis with a cuprophane dialyzer, but may be increased
during the use of a polyacrilonitrile dialyzer [40].
The PTH-calcium curve in humans
Studies in normal individuals
Studies in normal humans and animals have indicated that
intact PTH is secreted in a pulsatile fashion [138—142]. The
pulsatile peaks of the intact P1'H represent an increase of
approximately 30 to 50% from baseline levels [140, 141]. In
several studies, the amplitude of the PTH peak was reported to
be greater at night than during the day [138, 139, 141, 143]. The
observation of episodic secretion of PTH is similar to the
secretory patterns of other endocrine hormones [144—148]. The
pulsatile nature of secretion by these hormones is believed to be
an important modulator of target organ responses [144—146,
149]. Whether this is true for PTH still remains to be deter-
mined.
In 1988, Brent et al using an IRMA assay for intact PTH
evaluated the PTH-calcium curve in normal individuals [5].
Hypocalcemia was induced by an infusion of sodium EDTA and
hypercalcemia by infusion of calcium gluconate. The relation-
ship between calcium and PTH was best represented as a
sigmoidal curve with basal, maximal, and minimal PTH levels
of 23, 100, and 6 pg/mi, respectively. Thus, the ratio of basal to
maximal PTH was 23% and the ratio of minimal to maximal
PTH was 6%. These values are remarkably similar to those in
normal calves obtained by Mayer and Hurst in an earlier study
[6]. Using a basal serum calcium value of 9.5 mg/dl to recalcu-
late the results of Mayer and Hurst, the basal to maximal PTH
ratio is 23% and the minimal to maximal ratio is 7%. In both of
these studies, the basal PTH value was positioned at the point
on the curve near the steep ascent; thus a small decrease in the
serum calcium produced a marked increase in PTH (Fig. lB).
Likewise, the induction of hypercalcemia would result in a
modest suppression of PTH from baseline values. In addition,
despite the induction of marked hypercalcemia in both studies,
a small but non-suppressible component of PTH secretion was
observed.
Results from a recent study in which hypo- and hypercalce-
mia were induced in postmenopausal women [150] were similar
to the findings reported in normal calves and humans [5, 6].
However, a direct comparison of PTH values with previous
studies in normal humans is not possible because a carboxy-
terminal PTH assay was used. Nevertheless, the ratio of basal
to maximal PTH was 27%. The ratio of minimal to maximal
PTH was 16%, however, this may be an overestimation because
the elimination of carboxy-terminal PTH may be delayed,
especially in an older population in whom the GFR is likely to
be decreased [34, 42, 128] and hypercalcemia may result in the
preferential secretion of the carboxy-terminal fragment [8, 48].
Nephrogenous cyclic AMP (NcAMP) is a marker of PTH
activity and thus should provide a biological assay for PTH
[151—153]. In the study by Gardin et al [154], the relationship
between NcAMP and serum ionized calcium was evaluated in
normal volunteers. By plotting NcAMP versus serum ionized
calcium, the relationship NcAMP and calcium is a sigmoidal
curve with a basal to maximal NcAMP ratio of 33%, and the
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minimal NcAMP level induced by hypercalcemia was approx-
imately 5% of the maximal NcAMP level. Thus, in normal
individuals, the NcAMP-ionized calcium relationship is remark-
ably similar to that between PTH and calcium [5].
Studies in patients with primary hyperparathyroidism
Although most studies performed in patients with 1° HPT
have used a carboxy-terminal assay for PTH, the data are
convincing with respect to several aspects of PTH secretion: (1)
in 10 HPT, lowering of the serum calcium from baseline
hypercalcemia induces a rapid and marked increase in PTH
secretion even before normal levels of serum calcium are
attained [155—160]; (2) in the hypercalcemia of malignancy or
other hypercalcemias of non-parathyroid origin, a reduction of
the serum calcium into the normal range does not increase PTH
levels [155—157]; and (3) in 1° HPT, increasing the serum
calcium from baseline hypercalcemia suppresses PTH [126,
153, 154, 160—162]. In most of these studies, a carboxy-terminal
PTH assay was used and the PTH-calcium curve was not well
defined. However, extrapolation of the results of Murray et al,
as obtained with a carboxy-terminal PTH assay, shows that the
basal to maximal PTH ratio was 33% and the minimal to
maximal PTH ratio was 18% [160]. In another study, performed
in five patients with 10 HPT, the basal to maximal nephrogenous
cyclic AMP ratio was 35% and the minimal to maximal ratio
was 5% [154].
Results from the above-cited studies indicate that patients
with 10 HPT respond appropriately to changes in serum calcium
except that the PTH-calcium curve is shifted to the right of
normal individuals. Furthermore, important information such
as an accurate assessment of maximal PTH response to hy-
pocalcemia, and the ratio of basal to maximal PTH and minimal
to maximal PTH, are difficult to obtain from these studies.
Finally, little work has been done to determine whether in 10
HPT there is a difference in the dynamics of PTH secretion in
the subset of patients primarily with stone disease versus those
primarily with bone disease [163—166]. Differences in the mass
of the parathyroid gland (greater in bone disease) and calcitriol
levels (higher in stone disease) are known to be present in
patients with these two subtypes of 10 HPT [163, 164, 166].
Thus, in patients with 1° HPT, future studies of the PTH-
calcium curve using the IRMA assay for intact PTH should
provide information which will add to our understanding of this
common disorder.
Studies in patients with moderate renal failure
Clinical studies which have evaluated P1'H secretion in
patients with moderate renal failure are few and primarily focus
on the question of skeletal resistance to PTH. In the 1975study
by Llach et al [12], a carboxy-terminal PTH assay was used to
evaluate PTH secretion during EDTA-induced hypocalcemia in
patients with moderate renal failure, mean creatinine clearance
65 5 mlimin. By replotting the data so that determinations of
serum calcium and PTH are on the horizontal and vertical axis,
respectively, several parameters can be re-examined. The basal
to maximal PTH ratio is approximately 30%; it was not possible
to calculate this ratio in the normal volunteers because the basal
PTH value was in the undetectable range for the PTH assay.
The maximal PTH value is 2.5 times greater in the group with
renal failure than normals. In another study in patients with
moderate renal failure, a different carboxy-terminal PTH assay
was used to measure PTH during EDTA-induced hypocalce-
mia. If serum calcium and PTH are replotted on the vertical and
horizontal axis, respectively, the basal to maximal PTH ratio is
50% and the maximal PTH value is 1.3 times greater in the renal
failure than the normal group [167]. Because of the use of a
carboxy-terminal assay, it is not possible to directly compare
these two studies with others which have used the IRMA PTH
assay which measures intact hormone. Future studies using an
IRMA assay for PTH could provide important information on
the development of HPT during the evolution of renal failure.
Studies in dialysis patients
Because basal PTH levels are known to differ in hemodialysis
patients with the three prevalent forms of renal osteodystrophy-
osteitis fibrosa, LTAABD, and aplastic bone disease, we eval-
uated PTH-calcium curve in these three groups of patients [7].
Osteitis fibrosa is characterized by a marked elevation in PTH
levels, while in LTAABD and aplastic bone disease PTH levels
are only moderately increased or even normal. A description of
the differences in bone histology between the three groups is
provided earlier in this paper.
The objective was to assess whether the parathyroid gland
functioned differently in these three groups of hemodialysis
patients in whom the basal PTH levels and the expression of
PTH activity on bone were so different. Basal PTH levels were
approximately 7- to 11-fold higher in patients with osteitis
fibrosa (1075 179 pg/ml) than in patients with LTAABD (151
38 pg/nil) and ABD (94 19 pg/mi). As shown in Figure 2,
maximal PTH levels were only 4- to 7-fold greater in patients
with osteitis fibrosa (1952 519 pg/mI vs. 443 94 and 264
47 pg/ml in LTAABD and ABD, respectively). These differ-
ences indicate that in osteitis fibrosa, there is greater stimula-
tion of PTH at baseline. The ratio of basal to maximal PTH was
61% in osteitis fibrosa as compared with 33% in LTAABD and
36% in aplastic bone disease. These differences were observed
even though the baseline ionized calcium level in the three
groups were not significantly different. Despite differences in
the ratio of basal to maximal PTH between these groups, this
ratio was higher in all three groups of dialysis patients than in
normal volunteers in whom it was approximately 23% [5].
Whether changes in the ratio of basal to maximal PTH is unique
to the HPT of renal failure or is observed with other causes of
20 HPT remains to be determined. However, a study in dogs
with dietary-induced vitamin D deficiency, another condition
known to induce 2° HPT, has shown that the ratio of basal to
maximal PTH did not increase although maximal PTH levels
increased by fourfold and serum caicitriol levels were low [168].
The reason for the differences in parathyroid gland secretory
capacity observed in dialysis patients is not fully understood.
Clinical observations [27, 28, 31, 54, 57, 169] and in vitro studies
[110-112, 169] have suggested that aluminum exposure may
decrease PTH secretion and thus retard the development of
marked 2° HPT; this may be important in patients with
LTAABD. The majority of our patients with aplastic bone
disease had diabetes, a disease which may slow the develop-
ment of HPT [59, 170]. However, aplastic bone disease with
only moderate HPT is also reported in non-diabetic patients on
dialysis [7, 39]. Other factors known to affect the development
of parathyroid hyperplasia, such as the serum calcium [4,9, 10],
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Fig. 2A. The PTH-calcium relationship is shown in three groups of hemodialysis patients who were separated according to the form of renal
osteodystrophy, low-turnover aluminum bone disease (LTAABD2) (-j-), osteitisfibrosa (-H—), and aplastic bone disease (--), that was present.
In hemodialyis patients with osteitis fibrosa, PTH values were significantly greater at every level of ionized calcium than in patients with LTAABD
and aplastic bone disease. No differences were observed between the LTAABD and aplastic bone disease groups. Values are mean SE; *P <
0.05. B. The PTH-calcium relationship is presented with PTH as a percent of the maximal PTH level. The conversion of PTH to percent was
performed to factor for differences in absolute PTH values, and thus provide an assessment of parathyroid cell sensitivity (slope of the
PTH-calcium curve). The slope was steeper in patients with osteitis fibrosa than in the other two groups. The set point (S) of calcium was greater
in hemodialysis patients with osteitis fibrosa than in the other two groups. Reprinted with permission from Nephrology, Dialysis and
Transplantation.
phosphorus [171—173], and calcitriol [174, 1751, and the calce-
mic response to PTH [12—14, 43, 176] may play important roles
in the development of HPT. However, it is difficult to attribute
differences in any of these factors that would account for the
marked variation in PTH levels observed in the different forms
of renal osteodystrophy.
As shown in Figure 2B, the set point of calcium and the slope
of the PTH-calcium curve, with PTH expressed as a percent of
maximal PTH, were also determined. The set point of calcium
was greater in the group with osteitis fibrosa than in the other
two groups. The respective ionized calcium values were 4.72
0.08, 4.44 0.16, and 4.36 0.08 mg/dl for osteitis fibrosa,
LTAABD, and aplastic bone disease, respectively, and were
thus greater in osteitis fibrosa than the other two groups (P <
0.03). These data would indicate that PTH secretion is stimu-
lated at a higher serum calcium concentration in osteitis fibrosa.
This may reflect the greater mass of the parathyroid gland in
osteitis fibrosa. Based on an extrapolation of the data obtained
in normal volunteers [5], the set point of calcium was approx-
imately 4.75 mg/dl. This value is similar to the set point of
calcium in hemodialysis patients with osteitis fibrosa who have
a much greater parathyroid gland mass. A similar observation
has been made recently by Salusky in children with osteitis
fibrosa on CAPD as compared with normal volunteers (personal
communication). However, in patients with 10 HPT, the set
point of calcium is considerably higher [155—160]. Furthermore,
in vitro studies of abnormal parathyroid cells derived from both
adenomatous and hyperplastic parathyroid glands have found
that these abnormal parathyroid cells have a higher set point of
calcium than normal parathyroid cells [72, 98, 101—103]. Thus,
it is reasonable to question why should the dialysis patient with
osteitis fibrosa and marked parathyroid gland hyperplasia have
a set point of calcium that is similar to the normal individual. A
likely explanation may be that in 10 HPT, there is a more
efficient system for calcium reclamation from the bone and
kidney in addition to enhanced gut absorption of calcium.
Perhaps a more appropriate comparison of the effect of para-
thyroid cell mass on the set point of calcium would be between
groups with similar renal function. Thus, in this instance, the
set point of calcium is greater in patients with 10 HPT than in
normals, and greater in dialysis patients with osteitis fibrosa
than in dialysis patients with LTAABD or aplastic bone dis-
ease.
The slope of the PTH-calcium curve, which should reflect the
sensitivity of the parathyroid cell (PTH production per parathy-
roid cell), was greater in the group with osteitis fibrosa than
LTAABD (P < 0.04). The value in the group with aplastic bone
disease was intermediate between the other two groups.
Since the same IRMA assay for intact PTH was used for the
study in dialysis patients as well as in the study by Brent et al
[5], certain comparisons can be made between the normal
individuals and the three groups of hemodialysis patients with
the different forms of renal osteodystrophy. However, as stated
previously, this comparison may be affected by possible differ-
ences in the metabolic clearance rate of intact PTH. Baseline
PTH levels were greater in hemodialysis patients with osteitis
fibrosa, LTAABD, and aplastic bone disease than in normal
individuals by a factor of 50, 7, and 4, respectively. Conversely,
the ratio for maximal PTH in patients with osteitis fibrosa,
LTAABD, and aplastic bone disease versus normal volunteers
was lower, 19, 5, and 3, respectively. These results suggest:
First, there is a much greater secretory capacity of the parathy-
roid gland in renal failure, especially in patients with osteitis
fibrosa. Second, comparing the hemodialysis patient to the
normal individual, the ratio of basal PTH is greater than the
ratio of maximal PTH. This is especially true for patients with
osteitis fibrosa in whom contrasted with the normal individual,
the ratio of basal PTH is 50 and the ratio of maximal PTH is 19.
This difference in ratios stems from the fact that the basal PTH
level was 61% of maximal PTH in hemodialysis patients with
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Fig. 3A. The correlation between the basal PTH level and the maximal PTH level (stimulated by hypocalcemia) is shown for the three groups of
hemodialysis patients with ddferent forms of renal osleodystrophy, Symbols are: (Ix) LTAABD; (0) osteitis fibrosa; () aplastic bone disease. The
correlation was significant when the three groups were evaluated together and separately (not shown). A log-log comparison was used because of
the unequal distribution of the PTH values. r = 0.87; P < 0.001. B. The correlation between the minimal PTH level, as induced by hypercalcemia,
and the maximal PTH level, as stimulated by hypocalcemia, is shown for the three groups of hemodialysis patients with different forms of renal
osteodystrophy. The correlation was significant when the three groups were evaluated together and separately (not shown). A log-log comparison
was used because of the unequal distribution of the PTH values. r = 0.93; P <0.001. Reprinted with permission from Nephrology, Dialysis and
osteitis fibrosa and 23% in normal individuals. The above
findings would indicate that HPT in patients with osteitis fibrosa
is achieved not only by an enlargement in gland size, but also by
enhanced PTH secretion in the baseline state. This may occur
because of a limitation in the growth of the gland or may be due
to changes in the cell cycle of parathyroid cells. The proportion
of actively secreting parathyroid cells may be increased due to
a lengthened secretory phase and a shortened quiescent phase
[63, 124, 177]. Whatever the reason, the end result is enhanced
PTH secretion in the baseline state at the cost of a decreased
secretory reserve. Whether this adaptation is unique to renal
failure or is observed in other causes of HPT such as a
parathyroid adenoma or malabsorption has not been deter-
mined. However, at least in an animal model of 20 HPT that was
induced by vitamin D deficiency, maximal PTH increased by
fourfold, but the ratio of basal to maximal PTH did not increase
[168]. Although the magnitude of HPT was considerably less in
the animal model than in hemodialysis patients with osteitis
fibrosa, it at least suggests that a deficiency of calcitriol may not
be the only factor for an increase in the ratio of basal to maximal
PTH. Finally, another interesting finding was that the ratio of
minimal to maximal PTH was approximately three times greater
in the dialysis patients than in the normal volunteers. This may
be due to an increase in the number of parathyroid cells in the
active secretory phase [63, 124, 177] and a greater mass of cells
in the dialysis patient. These factors may be responsible for the
greater non-suppressible component of PTH secretion during
hypercalcemia.
In our studies of hemodialysis patients, a significant correla-
tion was observed between basal PTH and maximal PTH, and
minimal PTH and maximal PTH (Fig. 3). While this observation
does not prove that PTH measurements directly correlate with
parathyroid gland mass, this assumption is supported by the
findings of McCarron et al in renal transplant recipients [601 and
Johnson et al in dialysis patients [178]. In both studies there was
a significant correlation between either the basal PTH level or
the PTH response to hypocalcemia and the mass of the para-
thyroid gland at the time of parathyroidectomy.
Treatment of renal osteodystrophy in the dialysis patients and
its effect on the PTH-calcium curve
Desferrioxamine for dialysis patients with low turnover
aluminum-associated bone disease
Several studies have demonstrated that PTH secretion during
hypocalcemia is decreased in dialysis patients with LTAABD
as compared with osteitis fibrosa [7, 28, 57]. While treatment
with desferrioxamine (DFO) has been shown to improve the
bone disease in LTAABD even though basal PTH levels do not
change [179, 1801, the effect of DFO treatment on parathyroid
gland function has been evaluated only by our group [54]. We
found that DFO treatment for one year improved the bone
disease, but did not increase maximal PTH levels. As shown in
Figure 4, DFO shifted the PTH-calcium curve to the right and
the set point of calcium increased from 8.80 0.16 to 9.26
0.18 mg/dl, P < 0.02. Thus, for the same calcium concentration
at normal serum calcium levels (9 to 10.5 mg/dl), the PTH level
was higher after DFO treatment. Therefore, although DFO
treatment did not change maximal PTH level as stimulated by
hypocalcemia, basal PTH levels were functionally greater after
DFO because PTH levels were higher in the normal range of
serum calcium.
Calcitriol treatment for dialysis patients with osteitis fibrosa
Since the availability of oral calcitriol in the 1970's, oral and
later intravenous calcitriol have been used for the treatment of
20 HPT in dialysis patients [16—18, 20, 21, 181—1851. In most
studies, the basal PTH level decreased, the serum calcium
concentration increased, and the bone disease improved. How-

















2 2 00 2
10 100 1000
Transplantation.
780 Felsenfeld and Llach: PTH in CRF
7 8 9 10 11 12
Serum calcium, mg/dl
Fig. 4. The PTH-calcium relationship is shown in hemodialysis pa-
tients with low-turnover aluminum bone disease before (-- and after
(--0--) one year of treatment with DFO. Although maximal PTH levels
were not significantly different, the PTH-calcium curve was shifted to
the right after DFO treatment. Thus, when the serum calcium was
greater than 8.75 mg/dl, the PTH level for the same serum calcium
concentration was greater after DFO treatment. Values are mean SE;
*p < 0.05. Reprinted with permission from Kidney International.
not possible to determine whether the reduction in PTH was
due to the calcitriol-induced increase in the serum calcium or a
direct effect of calcitriol on the parathyroid gland. This is
especially difficult to determine since the PTH-calcium relation-
ship is not linear, but sigmoidal; thus, a small change in the
serum calcium in the steepest part of the PTH-calcium curve
will result in a large change in VI'H [5, 7, 211. Evidence that
calcitriol directly suppresses PTH messenger RNA has been
convincingly demonstrated in both in vitro and in vivo studies
by Silver and colleagues [65, 76—78] and by others [79, 186,
1871. The use of the PTH-calcium curve in clinical studies has
provided a means by which the independent effect of caicitriol
and calcium on PTH secretion could be separated. Thus,
throughout a range of serum calcium values, the PTH level
could be evaluated for the same serum calcium concentration
before and after calcitriol. Furthermore, the determination of
the slope of the PTH-calcium curve and the set point of calcium
does provide additional information about the effect of cal-
citriol.
Several studies in dialysis patients have evaluated the effect
of calcitriol on the PTH-calcium relationship. In one of the first
studies to use intravenous calcitriol, Slatopolsky et al, after a
three week control period, administered intravenous calcitriol
following every hemodialysis during a eight week period, and
then re-evaluated the patients for three weeks after calcitriol
was discontinued [20]. Calcitriol treatment resulted in a reduc-
tion in PTH levels before any increase in serum calcium. Also
of interest was the finding of an approximately threefold greater
decrease in PTH for a similar increment in serum calcium when
the increment was induced by calcitriol as opposed to calcium
carbonate. These findings suggest a direct suppressive effect of
calcitriol on PTH secretion in the hemodialysis patient. Later
Delmez et al [182] administered intravenous calcitriol to hemo-
dialysis patients with 20 HPT for two weeks and evaluated the
PTH response to hypo- and hypercalcemia. The results of this
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Fig. 5. The PTH-calcium relationship is shown in hemodialysis pa-
tients with osteitis fibrosa before (•) and after (0) 10 weeks of
intravenous calcitriol (2 jsg after every hemodialysis). Treatment with
intravenous calcitriol resulted in a significant decrease in PTH levels at
almost every concentration of calcium. Values are mean SE;
0.05. Reprinted with permission from Kidney International.
secretion independent of the serum calcium concentration.
However, the use of different patients during the induction of
hypo- and hypercalcemia did not allow the construction of a
sigmoidal PTH-caicium curve for each patient. Furthermore,
the set point of calcium was calculated from data derived only
during the induction of hypercaicemia. Thus, it is difficult to be
certain that a reduction of the set point of calcium was observed
as a result of caicitriol treatment.
In a previous study, we treated nine hemodialysis patients
with marked 2° HPT, mean basal PTH level by IRMA assay 902
126 pg/mi, with intravenous calcitriol [21]. These patients
received 2 pg of intravenous calcitriol after each hemodialysis
for a ten week period. The PTH-calcium curve was studied by
the induction of hypo- and hypercalcemia before and after
calcitriol treatment. After ten weeks of calcitriol, the maximal
PTH level decreased from 1661 485 to 1031 280 pglml (P <
0.05) and the minimal PTH level from 281 76 to 192 48
pg!ml (P < 0.05). As shown in Figure 5, calcitriol reduced the
PTH level at essentially every serum calcium concentration.
However, neither the set point of calcium nor the slope of the
PTH-calcium curve was significantly different after ten weeks
of calcitriol. These findings suggest that caicitriol: (1) reduced
the functional mass of parathyroid cells (based on the lower
maximal PTH); (2) did not change the serum calcium concen-
tration at which PTH was stimulated (no difference in the set
point of calcium); and (3) did not change the sensitivity of the
parathyroid cell (no difference in the slope of the PTH-calcium
curve with PTH as a percent of maximal PTH).
After the completion of the above study, six patients contin-
ued to receive intravenous calcitriol and were re-evaluated after
42 weeks of calcitriol therapy [55]. However, during weeks 10
through 42, these six patients were not part of a formal study,
and as a result their calcium-phosphate product was not moni-
tored as closely as during the original study; consequently, two
non-compliant patients developed a marked elevation in their
calicum-phosphate product during this interval. As shown in
Figure 6A, continued treatment with calcitriol resulted in a
progressive decrease in serum PTH levels for a similar serum
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calcium was not different between 0, 10, and 42 weeks, the
slope of the PTH-calcium curve was decreased at 42 weeks
(P < 0.05) as compared with both 0 and 10 weeks (Fig. 6B). The
decreased slope of the PTH-calcium curve at 42 weeks would
suggest that the sensitivity of the parathyroid cell decreased as
a result of long-term calcitriol therapy. In the two patients in
whom serum phosphate levels were poorly controlled, intrave-
nous calcitriol did not further decrease PTH levels after 10
weeks.
In a recent study in which intravenous calcitriol was used to
treat hemodialysis patients with marked secondary hyperpara-
thyroidism, Malberti, Surian and Cosci reported results similar
to our previous studies [188]. In that study, ten patients with
basal PTH levels of 1069 233 pg/mI (as measured with an
IRMA assay for intact PTH), were treated with 2 tg of
intravenous calcitriol after every hemodialysis for four months.
Treatment with calcitriol reduced basal PTH levels from 1069
233 to 354 90 pg/ml (P <0.05) and maximal PTH levels were
reduced from 1440 358 to 914 178 pg/mi (P < 0.05).
Based on our studies in hemodialysis patients [7, 21, 31] and
the study by Brent et al in normal humans [5], it would appear
that the slope of the PTH-calcium curve is less steep in dialysis
patients than in normal individuals. Furthermore, treatment
with calcitriol appears to further decrease the slope instead of
restoring it to the steeper level observed in normal humans.
These findings would suggest that the sensitivity of the para-
thyroid cell is less in renal failure than normal humans, and
calcitriol treatment may further decrease the sensitivity. The
reason for this finding may be related to the fact that the
parathyroid gland mass is much larger in renal failure. Thus, for
calcitriol treatment to decrease PTH secretion, which has been
adequately demonstrated since PTH levels are decreased
throughout the PTH-calcium curve after calcitriol, either the
number of parathyroid cells must decrease, PTH production per
cell must diminish, or a combination of both. As compared with
baseline, maximal PTH levels decreased by more than 50%
after 42 weeks of ealcitriol. Although the parathyroid gland
mass was not determined, it is unlikely that the mass of the
parathyroid gland decreased commensurately during the same
time period. Thus, if absolute PTH secretion decreased propor-
tionally more than the mass of the parathyroid gland, then PTH
production per cell must decrease, and this as observed would
produce a reduction in the slope of the PTH-calcium curve.
Of particular interest is the recent report of a hemodialysis
patient in whom the PTH-calcium curve was studied before and
after two months of intravenous calcitriol treatment, and after
7/8 parathyroidectomy [188]. Respective maximal PTH levels
by IRMA assay for intact PTH were 1540 and 1251 pg/mi before
and after calcitriol and 145 pg/ml after parathyroidectomy. The
parathyroidectomy resulted in an increase in the slope of the
PTH-calcium curve. This would indicate that the sensitivity of
the parathyroid cell increased (PTH production for a change in
calcium). Although one must be cautious to base a conclusion
on findings observed in a single patient, the results do serve to
illustrate possible differences between lowering PTH levels by a
surgical reduction in parathyroid mass (parathyroidectomy) and
calcitriol treatment. Both have been shown to effectively de-
crease PTH levels, but with calcitriol it is likely that secretion of
PTH decreases proportionally more than a decrease in the mass
of parathyroid cells.
Hysteresis of the PTH-calcium curve
Hysteresis is defined as the failure of a property that has been
altered by an external agent to return to its original value when
the cause of the alteration is removed. In a study in normal
volunteers, Conlin et al observed that the PTH level for the
same serum calcium concentration was lower during the recov-
ery from hypocalcemia than the induction of hypocalcemia and
higher during the recovery from hypercalcemia than the induc-
tion of hypercalcemia; this finding was termed hysteresis [50].
Hysteresis was also observed in hemodialysis patients by
Cunningham et al who observed that the PTH level for the same
serum calcium concentration was lower during the recovery
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Fig. 6A. The effect of prolonged intravenous calcitriol treatment on the PTH-calcium curve is shown in hemodialysis patients with osteitisfibrosa.
The PTH-calcium curve was evaluated at baseline (0 weeks; --) and after 10 (.0.) and 42 (--U--) weeks of intravenous calcitriol. Intravenous
calcitriol resulted in a progressive decrease in basal and hypocalcemia-stimulated PTH levels. Values are mean s; P < 0.05. B. The
PTH-calcium curve is shown with maximal PTH converted to 100%. The slope of the PTH-calcium curve (defined in Fig. IB) should represent the
sensitivity of the parathyroid cell (change in PTH for a change in calcium). As compared with 0 weeks, the slope of PTH-calcium curve is decreased
after 42 weeks of intravenous calcitriol administration (P < 0.05). Reprinted with permission from the Journal of the American Society of
Nephrology.
782 Felsenfeld and Liach: PTH in CRF
0
3 3.5 4 4.5 5 5.5 6
Ionized calcium, mg/dl
Fig. 7. The s,grrioidal PTH-calcium curve developed during the induc-
tion of hypocalcemia and hypercalcemia from baseline (- is con-
trasted with the mean PTH-calcium curve developed as the ionized
calcium concentration was increased during the recovery from the
nadir of hypocalcemia (--•--). The difference in the PTH-calcium
curves is known as hysteresis. Values are mean SE; *D < 0.05.
Reprinted with permission from the Journal of the American Society of
Nephrology.
[53]. In an earlier study, Adami et al had observed that PTH
levels were higher during the recovery from hypercalcemia than
during the induction of hypercalcemia [189]. This observation
was made both in hemodialysis patients and in patients with a
vitamin D deficiency. Thus, the phenomenon of hysteresis has
been observed in normal individuals and in conditions, such as
renal failure and vitamin D deficiency, in which 2° HPT is
present.
In a recent study in hemodialysis patients [52], we observed
hysteresis during the induction of and recovery from hypocal-
cemia (Fig. 7). Furthermore, several additional observations
regarding the PTH-calcium relationship were made. As shown
in Figure 8, the presence of hysteresis appeared to be depen-
dent on the basal serum calcium concentration. Thus, with a
baseline serum ionized calcium between 4.5 and 5.5 mgldl, a
hysteretic response, defined as the area between the PTH-
calcium curves obtained during the induction of hypocalcemia
and the recovery from hypocalcemia, was observed (Fig. 8 A
and B). However, as the baseline serum ionized calcium
concentration progressively decreased, the hysteretic response
was markedly diminished (Fig. 8 C and D). Furthermore, as
shown in Figure 9, the basal serum calcium concentration
appeared to affect the PTH-calcium curve during the induction
of hypocalcemia, but not the PTH-calcium curve obtained
during the recovery from hypocalcemia. In addition, the basal
serum calcium and the serum calcium at which the two PTH-
calcium curves intersected (induction of and recovery from
hypocalcemia) were virtually identical: 4.61 .13 versus 4.61
.12 mg/dl. The basal serum calcium also correlated with the
serum calcium at the intersection of the two curves (r = 0.87, P
< 0.001). The finding that the PTH level for the same serum
calcium concentration was lower during the recovery from
hypocalcemia than the induction of hypocalcemia and was
higher during the recovery from hypercalcemia than the induc-
tion of hypercalcemia suggests that the parathyroid gland may
sense directional changes in the serum calcium. In addition, the
finding that the PTH-calcium curve appears to be influenced by
The PTH-calcium curve after renal transplantation
While a large number of studies have focused on the evolu-
tion of 2° HPT in renal failure, the adaptation of the parathyroid
gland to the restoration of renal function by renal transplanta-
tion has not been well studied. in the case of a well-functioning
renal transplant, factors such as a calcitriol deficiency [190—
194], hyperphosphatemia [190, 192], and skeletal resistance to
calcemic action of PTH [14], all of which are important for the
induction of 2° HPT during the evolution of renal failure, are no
longer present. In this instance, the concern is how a hyper-
plastic parathyroid gland adapts to a situation in which HPT is
no longer necessary nor desirable.
While the incidence of hypercalcemia in the post-transplant
period has probably decreased in the past ten years due to
better control of HPT during maintenance dialysis, persistent
HPT and hypercalcemia are still observed in the renal trans-
plant recipient [38, 190, 195—197]. While it has been stated that
during hypercalcemia the parathyroid gland preferentially se-
cretes the inactive carboxy-terminal fragment of PTH [8, 48],
our findings in dialysis patients would indicate that during
hypercalcemia, the minimal PTH level, as measured by an
assay for intact PTH, is approximately 20 to 25% of maximal
PTH [7, 21, 55]. Thus, the non-suppressible component of PTH
secretion and the large size of the parathyroid gland may
contribute to the persistent elevation of intact PTH after renal
transplantation [38, 198].
In an excellent review by Parfitt, potential mechanisms for
the involution of the parathyroid gland after renal transplanta-
tion are discussed [63]. The low rate of cell turnover in the
normal human parathyroid gland, the poor development of any
mechanism for cell deletion, and the slow rate at which para-
thyroid glands become smaller in response to hypercalcemia all
suggest to Parfitt that the hyperplastic parathyroid gland in the
human involutes slowly following renal transplantation [63]. On
the other hand, recent reports in dialysis patients have noted a
decrease in parathyroid gland size, as measured by sensitive












the basal serum calcium concentration suggests that the para-
* thyroid gland may adjust to the ambient serum calcium.
Two recent studies have provided additional information
about the phenomenon of hysteresis. Grant, Conlin and Brown
studied the effect of pulsatile increases in the rate of the calcium
chelator, citrate, on the serum calcium and PTH; similar studies
* * were performed during the induction of hypercalcemia with
calcium gluconate [511. They observed that pulsatile increases
in the rate of citrate administration stimulated PTH more than a
constant infusion of citrate despite no difference in the magni-
tude of hypocalcemia. However, pulsatile increases in the rate
of calcium infusion did not induce a more marked decrease in
PTH than if the serum calcium was increased at a constant rate.
Thus, the authors questioned whether hysteresis is a function of
a rate dependent change in PTH secretion and not the result of
a directional change in the serum calcium. Finally, Kwan et al
have reported that after four weeks of calcitriol treatment in
hemodialysis patients, hysteresis was no longer observed even
though it was present before treatment with calcitriol [611. The
above-cited studies raise intriguing questions about the phe-
nomenon of hysteresis and indicate the need for additional
studies to help clarify these issues.
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[181, 199]. However, markedly enlarged parathyroid glands did
not respond as well as smaller parathyroid glands [1991. At a
cellular level, it was noted that calcitriol induced parathyroid
cell death in the rat by a process termed "apoptosis" [2001. As
opposed to necrosis, apoptosis is characterized in its early
stages by condensation of the nuclear chromatin and fragmen-
tation of the nucleus [201, 2021. Whether apoptosis is involved
in the involution of the parathyroid gland following renal
transplantation is not known. In one study in which parathy-
roidectomy was performed in 17 renal transplant recipients at a
mean interval of 43 6 months after transplantation, the
predominant histologic finding was asymmetric parathyroid
hyperplasia [203]. However, parathyroidectomy was performed
in this group of patients because of clinical evidence of persis-
tent hyperparathyroidism. Whether the involutional process is
more complete in asymptomatic renal transplant recipients is
not known. Unfortunately an appropriate animal model to study
this question would require prolonged renal failure to induce
chronic 20 HPT followed by a successful renal transplant before
an evaluation of the parathyroid gland could be performed.
We are aware of only one study in which parathyroid gland
function was evaluated in renal transplant recipients [601. In
that study, the PTH-calcium curve was evaluated in 15 renal
transplant recipients with persistent HPT and these results were
contrasted with those obtained in eight normal volunteers.
Selection for the study was based on persistent hypercalcemia
and inappropriately elevated PTH levels which were measured
by two different radioimmunoassays, a bi-terminal (amino and
carboxy) and a carboxy-terminal assay. The former PTH assay
appeared to be more sensitive to changes in the serum calcium.
Pertinent results included a 7.5-fold greater maximal PTH level
in renal transplant recipients than normals, a basal to maximal
PTH ratio of approximately 25% in renal transplant recipients,
and a highly significant correlation between the i.WTH response
to hypocalcemia and the size of the parathyroid gland at
parathyroidectomy. Because of the different PTH assay used in
this study, it is not possible to make direct comparisons with
previously discussed studies. Nevertheless, these findings
would suggest that this group of renal transplant recipients had
significant residual parathyroid hyperplasia, but based on the
normal ratio of basal to maximal PTH, the parathyroid glands in
these patients did not appear to be stimulated at basal serum
calcium, However, the latter may be a misleading conclusion
since hypercalcemia was present in these patients.
B Basal ionized calcium 4.5—5 mg/dlA Basal ionized calcium 5—5.5 mg/dl
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Fig. 8. Because of the wide dispersion of basal ionized calcium concentrations and, as a consequence, the level of ionized calcium at which
maximal PTH stimulation was observed, the PTH-calcium curves were divided according to the basal ionized calcium concentration. A through
D illustrate how the basal calcium concentration influences the configuration of the PTH-calcium curve. Values are mean SE. Symbols are:
(g-) induction; (--•--) recovery. Reprinted with permission from the Journal of the American Society of Nephrology.
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Fig. 9A. Composite of the PTH-calcium curves obtained during the induction of hypocalcemia. As the range of basal serum calcium decreases,
the PTH-calcjum curve shifts further to the left. Values are mean SE. B. Composite of the PTH-calcium curves obtained during the recovery from
hypocalcemia. The four curves are similar and do not appear to be influenced by the PTH-calcium curve obtained during the induction of
hypocalcemia. Values are mean SE.
The aforementioned study by McCarron et a! [60] focuses on
a select group of renal transplant recipients who because of
their hypercalcemia were expected to have the most severe
HPT. However, information is lacking on the natural course of
HPT after renal transplantation. While it may not be possible to
study pathologic changes of the parathyroid gland, a study of
parathyroid function (PTH-calcium curve) with a sensitive
assay for intact PTH could provide important information about
any involutional changes in the parathyroid gland which may
occur after renal transplantation. In such a study, it should be
possible to evaluate the PTH-calcium curve at regular intervals
after renal transplantation. The maximal PTH level should
provide information about the secretory capacity of the para-
thyroid gland; it should also be possible to study the sensitivity
of the parathyroid gland as well as the set point of calcium.
Finally, such an evaluation of parathyroid function could be
complemented with sensitive imaging techniques which could
provide information about involutional changes in parathyroid
gland size [181, 199].
Summary
The concept that the PTH-calcium curve is representative of
parathyroid function has been discussed. Comparisons of para-
thyroid function have been made between normal humans and
hemodialysis patients and also between hemodialysis patients
with different forms of renal osteodystrophy. From these com-
parisons, it is apparent that the magnitude of HPT is much
greater in patients with renal failure than in normal humans, and
as represented by the ratio of basal to maximal PTH, the
parathyroid gland appears to be stimulated at basal serum
calcium levels in hemodialysis patients. Similarly, based on an
analysis of the PTH-calcium curve, we were able to determine
that several differences in parathyroid function were present in
hemodialysis patients with different forms of renal osteodystro-
phy. As compared to hemodialysis patients with LTAABD and
aplastic bone disease, patients with osteitis fibrosa have a
greater magnitude of hyperparathyroidism, a greater sensitivity
of the parathyroid cell (slope), a higher set point of calcium, and
greater PTH stimulation at basal serum calcium (ratio of basal
to maximal PTH). Calcitriol treatment of hemodialysis patients
with osteitis fibrosa resulted in a significant decrease in PTH
throughout the PTH-calcium curve and also reduced the sensi-
tivity (slope) of the PTH-calcium curve. The concept of hyster-
esis has been discussed as well as the role that the ambient basal
serum calcium concentration may have on the determination of
the PTH-calcium curve. Finally, the effect that successful renal
transplantation has on HPT has been examined. In conclusion,
we believe that the PTH-calcium curve provides a reliable
assessment of parathyroid function, and as such, has consider-
able application for the study of parathyroid disorders in the
clinical setting.
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